Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $79.00

Definium Therapeutics (NASDAQ:DFTX) had its price objective lifted by Robert W. Baird from $75.00 to $79.00 in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They currently have an outperform rating on the stock.

DFTX has been the subject of several other research reports. Piper Sandler reissued an “overweight” rating and issued a $75.00 price target (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Bank of America began coverage on shares of Definium Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $75.00 price objective on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $66.00 price objective on shares of Definium Therapeutics in a research note on Friday, September 11th. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price objective on shares of Definium Therapeutics in a report on Monday. Finally, Canaccord Genuity Group set a $64.00 target price on shares of Definium Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $64.88.

Definium Therapeutics Stock Up 2.2%

Shares of NASDAQ:DFTX opened at $38.68 on Tuesday. The business’s 50 day simple moving average is $42.43 and its two-hundred day simple moving average is $30.92. The firm has a market cap of $5.20 billion, a P/E ratio of -11.28 and a beta of 2.23. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. Definium Therapeutics has a 52-week low of $8.77 and a 52-week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, research analysts forecast that Definium Therapeutics will post -3.02 EPS for the current fiscal year.

Insider Buying and Selling

In other Definium Therapeutics news, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the transaction, the insider directly owned 320,571 shares of the company’s stock, valued at $14,435,312.13. The trade was a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Matthew Wiley sold 2,867 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the sale, the insider owned 174,633 shares of the company’s stock, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 67,119 shares of company stock valued at $2,887,496 in the last 90 days. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Nykredit A S bought a new position in shares of Definium Therapeutics in the second quarter valued at approximately $45,000. Allworth Financial LP bought a new stake in Definium Therapeutics during the second quarter worth $110,000. Integrated Wealth Concepts LLC bought a new stake in Definium Therapeutics during the second quarter worth $159,000. NewEdge Advisors LLC purchased a new position in Definium Therapeutics in the second quarter worth $222,000. Finally, WINTON GROUP Ltd purchased a new position in Definium Therapeutics in the second quarter worth $240,000. 27.91% of the stock is owned by institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.